Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantation

Liver Transplantation

Volumn 12, Issue 1, 2006, Pages 105-111

  Bianchi, Giampaolo ^a,b   Nicolino, Francesco ^a   Passerini, Giorgia ^a,b   Grazi, Gian Luca ^a   Zappoli, Paola ^a   Graziani, Romina ^a   Berzigotti, Annalisa ^a   Chianese, Raffaela ^a,b   Mantovani, Vilma ^b   Pinna, Antonio Daniele ^a   Zoli, Marco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; HOMOCYSTEINE; PREDNISOLONE; TSUKUBAENOLIDE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GRAFT FAILURE; HUMAN; HYPERTENSION; LABORATORY TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK FACTOR; VEIN THROMBOSIS;

ADULT; AGE DISTRIBUTION; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HOMOCYSTEINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 33645101024     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20586     Document Type: Article

References (50)

1. Ritz E, Schwenger V, Wiesel M, Zeier M. Atherosclerotic complications after renal transplantation. Transpl Int 2000;13 (Suppl 1):S14-S19.
2. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 2000;70:SS41-SS45.
3. Plotkin JS, Johnson LB, Rustgi V, Kuo PC. Coronary artery disease and liver transplantation: the state of the art. Liver Transpl 2000;6(Suppl 1):S53-S56.
4. Romero M, Parera A, Salcedo M, Abeytua M, Banares R, de Diego A, et al. Cardiovascular risk factors and late cardiovascular disease in liver transplantation. Transplant Proc 1999;31:2364-2365.
5. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000;11:134-137.
6. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Sung 2001;181:475-479.
7. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, et al. Cardiovascular disease in cirrhosis - a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999;94:655-662.
8. Berzigotti A, Bonfiglioli A, Muscari A, Bianchi G, LiBassi S, Bernardi M, Zoli M. Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int 2005;25:331-336.
9. Mazuelos F, Abril J, Zaragoza C, Rubio E, Moreno JM, Turrion VS, Cuervas-Mons V. Cardiovascular morbidity and obesity in adult liver transplant recipients. Transplant Proc 2003;35:1909-1910.
10. Munoz SJ. Hyperlypemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis and management. Liver Transpl Surg 1995;1:29-38.
11. Blanco JJ, Herrero JI, Quiroga J, Sangro B, Gomez-Manero N, Pardo F, et al. Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events. Liver Transpl 2001;7:226-233.
12. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995;60:1057-1060.
13. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
14. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-1232.
15. Guilland JC, Favier A, Potier de Courcy G, Galan P, Hercberg S. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? 1. Basic data. Pathol Biol (Paris) 2003;51:101-110.
16. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002;7:227-239.
17. Mehra MR, Uber PA, Scott RL, Park MH, Milani RV. Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: homocysteine, C-reactive protein, and mean platelet volume. Transplant Proc 2002;34:1866-1868.
18. Herrero JI, Quiroga J, Sangro B, Beloqui O, Pardo F, Cienfuegos JA, Prieto J. Hyperhomocysteinemia in liver transplant recipients: prevalence and multivariate analysis of predisposing factors. Liver Transpl 2000;6:614-618.
19. Fernandez-Miranda C, Sanz M, de La Calle A, Loinaz C, Gomez P, Diaz-Rubio P, et al. Determinants of increased plasma homocysteine in 221 stable liver transplant patients. Clin Chem 2001;47:2037-2040.
20. Bosy-Westphal A, Ruschmeyer M, Czech N, Oehler G, Hinrichsen H, Plauth M, Lotterer E, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 2003;77:1269-1277.
21. Rose GA, Blackburn H. Cardiovascular Survey Methods. WHO Monograph Series, No 56. Geneva: World Health Organization, 1968.
22. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52.
23. Marchesini G, Manini R, Bianchi G, Sassi S, Natale S, Chierici S, et al. Homocysteine and psychological traits: a study in obesity. Nutrition 2002;18:403-407.
24. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998;62:1258-1260.
25. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999;96:12810-12815.
26. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
27. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
28. Ducloux D, Ruedin C, Gibey R, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 1998;13:2890-2893.
29. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drueke TB, Legendre C, et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994;9:1103-1108.
30. Cole DEC, Heather JR, Evrovski J, Langman LJ, Miner SES, Daly PA, Wong PY. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem 1998;44:2307-2312.
31. McKeever MP, Weir DG, Molloy A, Scott JM. Betaine: homocysteine methyltransferase: organ distribution in man, pig, and rat and subcellular distribution in the rat. Clin Sci 1991;81:551-556.
32. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-237.
33. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996:61:509-512.
34. Fernandez-Miranda C, Gomez P, Diaz-Rublo P, Estenoz J, Carillo JL, Andres A, Morales JM. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplantation 2000;14:110-114.
35. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994;69:1182-1193.
36. Albillos A, Cacho G, Barrios C, Alvarez-Mon M, Rossi I, Gomez-Arnau J, et al. Selective impairment of endothelium-mediated vasodilation in liver transplant recipients with cyclosporin A-induced hypertension. Hepatology 1998;27:332-338.
37. Fernandez LA, Lehmann R, Luzi L, Battezzati A, Angelico MC, Ricordi C, et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 1999;68:1532-1541.
38. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002;183: 595-599.
39. Gupta A, Robinson K. Hyperhomocysteinaemia and end stage renal disease. J Nephrol 1997;10:77-84.
40. Mor E, Helfmann L, Lustig S, Bar-Nathan N, Yussim A, Sela BA. Homocysteine levels among transplant recipients: effect of immunosuppressive protocols. Transplant Proc 2001;33:2945-2946.
41. Cook RC, Tupper JK, Parker S, Kingsbury K, Frohlich JJ, Abel JG, et al. Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. J Heart Lung Transplant 1999;18:420-424.
42. Wilcken DE, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981;61:743-749.
43. Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001;7:533-539.
44. Neuberger J. Liver transplantation. J Hepatol 2000; 32: 198-207.
45. Lerut J, Laterre PF, Roggen F, Ciccarelli O, Donataccio M, Martinez J, et al. Adult liver transplantation: UCL experience. Acta Gastroenterol Belg 1999;62:306-318.
46. Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 2002; 132:775-780.
47. Asfar S, Metrakos P, Fryer J, Verran D, Ghen C, Grant D, et al. An analysis of late deaths after liver transplantation. Transplantation 1996;61:1377-1381.
48. Fodinger M, Wolfl G, Fischer G, Rasoul-Rockenschaub S, Schmid R, Horl WH, et al. Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. Kidney Int 1999;55:1072-1080.
49. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jacques PF, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997;127:108-1092.
50. Jain AB, Kashyap R, Rakela J, Starzl TE, Fung JJ. Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg 1999;5:144-150.